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Smac mimetics induce inflammation and necrotic
tumour cell death by modulating macrophage activity
D Lecis*,1, M De Cesare1, P Perego1, A Conti1, E Corna1, C Drago2, P Seneci3,4, H Walczak5, MP Colombo1, D Delia1 and S Sangaletti*,1
Smac mimetics (SMs) comprise a class of small molecules that target members of the inhibitor of apoptosis family of
pro-survival proteins, whose expression in cancer cells hinders the action of conventional chemotherapeutics. Herein, we
describe the activity of SM83, a newly synthesised dimeric SM, in two cancer ascites models: athymic nude mice injected
intraperitoneally with IGROV-1 human ovarian carcinoma cells and immunocompetent BALB/c mice injected with murine Meth
A sarcoma cells. SM83 rapidly killed ascitic IGROV-1 and Meth A cells in vivo (prolonging mouse survival), but was ineffective
against the same cells in vitro. IGROV-1 cells in nude mice were killed within the ascites by a non-apoptotic, tumour necrosis
factor (TNF)-dependent mechanism. SM83 administration triggered a rapid inflammatory event characterised by host secretion
of TNF, interleukin-1b and interferon-c. This inflammatory response was associated with the reversion of the phenotype
of tumour-associated macrophages from a pro-tumoural M2- to a pro-inflammatory M1-like state. SM83 treatment was also
associated with a massive recruitment of neutrophils that, however, was not essential for the antitumoural activity of this
compound. In BALB/c mice bearing Meth A ascites, SM83 treatment was in some cases curative, and these mice became
resistant to a second injection of cancer cells, suggesting that they had developed an adaptive immune response. Altogether,
these results indicate that, in vivo, SM83 modulates the immune system within the tumour microenvironment and, through its
pro-inflammatory action, leads cancer cells to die by necrosis with the release of high-mobility group box-1. In conclusion, our
work provides evidence that SMs could be more therapeutically active than expected by stimulating the immune system.
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Resistance to death is a hallmark of cancer cells1 that renders
them unresponsive to chemotherapy. Chemoresistance is
often attributed to the inhibitor of apoptosis (IAP) proteins that
control many aspects of cellular life, including the response to
environmental stimuli, the regulation of cell death2 and cellular
motility.3,4 X-linked IAP (XIAP) is the only IAP to directly
interact with caspases, which occurs through conserved
domains named baculoviral IAP repeats.5 This interaction
hinders the activity of both initiator caspase-96 and effector
caspases-3 and -7.7 XIAP activity is antagonised by second
mitochondria-derived activator of caspases/direct IAP-
binding protein with low pI (Smac/DIABLO), which binds to
its baculoviral IAP repeats, thereby releasing the caspases6
and favouring the apoptotic cascade. Starting from this
observation, many groups have designed small peptidomi-
metics that mimic the structure of the N-terminal tetrapeptide
(AVPI) of Smac/DIABLO in order to prevent XIAP from
inhibiting caspases.8–10 These compounds, referred to as
Smac mimetics (SMs), enhanced the antitumour activity of
radiation or chemotherapeutic treatments in combination
experiments.11 Furthermore, they have been shown to
potentiate the cytotoxic effects of ‘death ligands’, in particular,
than that of tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL).9,12–14 Therefore, these compounds
have been proposed as novel cancer treatments and are
currently being tested, as part of combination therapies, in
clinical trials.2
Despite the ability of SMs to enhance the cytotoxicity of
other compounds, they are often ineffective in monotherapy.
Still, some cancer cell lines undergo a TNF-dependent
apoptotic process in response to the administration of a SM
alone. In fact, although these compounds were designed to
target XIAP, they also bind other IAPs, such as cellular IAP1
(cIAP1) and cIAP2, leading to their self-ubiquitination15,16 and
rapid proteasomal degradation.17,18 As cIAPs are negative
regulators of NF-kB-inducing kinase, their SM-triggered
depletion results in the stabilisation of NF-kB-inducing
kinase19 with consequent induction of the non-canonical
NF-kB pathway.17 In cell lines sensitive to these compounds,
this event is sufficient to trigger the secretion of high
1Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy; 2Institute of Biomolecular
Chemistry, National Research Council, Catania 25126, Italy; 3Department of Chemistry, University of Milan, Viale Golgi 19, Milan 20133, Italy; 4CISI scrl, Via Fantoli 16/
15, Milan 20138, Italy and 5Centre for Cell Death, Cancer and Inflammation, University College London, London WC1E 6BT, UK
*Corresponding author: D Lecis or S Sangaletti, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori,
Via Amadeo 42, Milan 20133, Italy. Tel: þ 39-02-23902846; Fax: þ 39-02-23903073; E-mail: daniele.lecis@istitutotumori.mi.it (DL) or Tel: þ 39-02-23903229;
Fax: þ 39-02-23903073; E-mail: sabina.sangaletti@istitutotumori.mi.it (SS)
Received 10.6.13; revised 11.10.13; accepted 15.10.13; Edited by M Piacentini
Keywords: Smac mimetics; ovarian cancer ascites; IAPs; innate immunity; inflammation
Abbreviations: SM, smac mimetic; IAP, inhibitor of apoptosis; TNF, tumour necrosis factor; XIAP, X-linked inhibitor of apoptosis; TRAIL, TNF-related apoptosis-
inducing ligand; PARP, poly (ADP-ribose) polymerase; LPS, lipopolysaccharides; HMGB-1, high-mobility group box-1; TNF-R1, TNF-receptor-1; TLR, toll-like receptor;
BMDM, bone marrow-derived macrophages; PMN, polymorphonuclear leucocytes
Citation: Cell Death and Disease (2013) 4, e920; doi:10.1038/cddis.2013.449
& 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13
www.nature.com/cddis
levels of TNF, thus killing the cells through an autocrine
or paracrine mechanism.17,18 Despite the clear in vitro
assessment of this process, the role of TNF in SM-induced
cell death in vivo is still controversial. In fact, the employment
of these compounds in pre-clinical models, either as mono-
therapy or in combination with other drugs, has resulted in
conflicting evidence,11,20,21 indicating a need to clarify the
mechanism of action of SMs in vivo.
One way to study the mechanisms of action of antitumoural
agents involves the use of animal models of cancer ascites.
The formation of ascites characterises the advanced-stage of
various types of tumours, especially ovarian carcinomas.
This condition depends on a mechanical constriction exerted
by the tumour and is determined by a peritoneal increase of
fluid production associated with decreased lymphatic absorp-
tion. Ascites is often the cause of death for ovarian cancer
patients, while rarely there is metastatic spread of tumour cells
outside the peritoneum.22 In peritoneal ovarian carcinoma-
tosis, the ascitic fluid represents the microenvironment in
which soluble factors are interchanged between cancer
and stromal and inflammatory cells, in order to support
tumour growth and invasion. This microenvironment also
promotes immunosuppression favouring tumour escape from
immune control. Thus, although the ascitic fluid is normally
enriched in immune cells, they are often anergic and
unable to elicit an antitumour immune response. Animal
models of cancer ascites facilitate the study of immune
cells such as macrophages in response to antitumoural
treatments.
Macrophages are plastic cells characterised by different
states of activation.23 Classically activated macrophages (M1)
and ‘alternatively’ activated macrophages (M2) represent
the two extremes in the spectrum of the macrophage
phenotype. Tumour-associated macrophages are classified
as M2 macrophages because of their cytokine expression
profile;24 they produce high amounts of immunosuppressive
cytokines such as interleukin-10 (IL-10) and, mostly in solid
tumours, share some tissue repair functions with fibro-
blasts.23,25 In contrast, M1 macrophages produce large
amounts of pro-inflammatory cytokines including interferon-g
(IFNg) and IL-12, and can be involved in the elicitation of
an effective antitumour immune response. The plasticity of
macrophages has suggested new therapeutic approaches
aiming to revert the M2 phenotype26 especially in tumours that
strictly relies on the macrophage infiltration such as ovarian
carcinomas. Accordingly, macrophages have been repro-
grammed in a mouse ovarian ascites model by modulating
NF-kB signalling.27
We recently described the synthesis of novel dimeric
molecules that target XIAP, cIAP1 and cIAP2.28,29 One of
these molecules, SM83, inhibited the growth of SM-sensitive
human mammary adenocarcinoma MDA-MB231 and rhab-
domyosarcoma Kym-1, but not of other cell lines. Here, we
use two murine xenograft models of cancer ascites to show
that SM83, when administered in monotherapy, increases the
survival of these mice by targeting tumour-associated macro-
phages. Through TNF, SM83 rapidly induces necrosis
of the intraperitoneally (i.p.) injected cancer cells, which are
otherwise completely resistant in vitro to the antitumoural
effects of SM83. Therefore, our work shows that SM83
displays different mechanisms of action in vitro and in vivo,
and that in vivo it exerts its antitumoural activity by stimulating
the immune system.
Results
SM83 sensitises the IGROV-1 ovarian carcinoma cell line
to the apoptotic effects of TRAIL. SM83 (Figure 1a) is a
novel inhibitor of XIAP, cIAP1 and cIAP2. When administered
to human IGROV-1 ovarian carcinoma cells, SM83 in
monotherapy at two doses had no inhibitory effect on cell
growth (Figure 1b). Instead, when administered together with
TRAIL, cell growth was substantially reduced to about
50 (2 ng/ml TRAIL) and 28% (10 ng/ml TRAIL) of that of
untreated cells, without a dose-dependent effect for
SM83. TRAIL treatment alone had a negligible effect at this
concentration, whereas SM83 monotherapy was ineffective
on a panel of other human cancer cell lines (A2780, H460,
SW48, HCT-116 and DLD-1 cells; data not shown).
The apoptotic effects of these treatments on IGROV-1 cells
at 3 and 24 h were assessed by western blotting (Figure 1c).
Treatment with SM83 alone decreased cIAP1 and cIAP2 to
almost undetectable levels already at 3 h. Treatment with
SM83 and TRAIL, at 24 h, strongly increased cleaved poly
(ADP-ribose) polymerase (PARP), a marker of activated
apoptosis. Similar results were obtained when cells were
treated with SM59 (Figure 1d). These results suggest that
SMs sensitise IGROV-1 cells to TRAIL-induced cell death
without causing death themselves.
SMs in monotherapy increase the survival of mice
bearing cancer ascites. SM83 and SM59 were then tested
in vivo using a murine xenograft model in which IGROV-1
cells are injected i.p. into athymic nude mice, leading to
ascites and death. Treatment with both SM83 (Figure 2a)
and SM59 (Figure 2b) increased mouse survival (Po0.05
versus control mice), but SM83 was slightly more effective
than SM59 (T/C% 180 versus 164). Furthermore, SM83
administration significantly reduced the formation of the
ascites (Figure 2c). Treatment with TRAIL alone did not
increase mouse survival, and the combination of TRAIL plus
SM83 had no additive effect (Figure 2a). These findings,
which are contrary to the in vitro results, suggest that SMs
alone slow the progression of ovarian ascites but are not
curative in these mice, whereas TRAIL alone is ineffective at
the concentration used.
To test whether the in vivo activity of SM83 was cell line-
specific or limited to immunodeficient mice, we used another
ascites model in which murine Meth A sarcoma cells are
injected i.p. into immunocompetent syngeneic BALB/c mice.
Similar to IGROV-1 cells, Meth A cells were not growth-
inhibited by SM83 in vitro (data not shown). In mice, SM83
reduced the progression of the ascites, seen as a smaller
increase in body weight (Figure 2d), and augmented the
median survival time from 15 days for untreated animals to
26 days (P¼ 0.0721; Figure 2e). Also in this model, combination
with TRAIL was not beneficial (data not shown). Moreover,
when mice cured by SM83 (4 of 14 mice tested) were
challenged with a new injection of 4 105 Meth A cells (twice
that of the first administration) none formed new ascites
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(data not shown). These results strongly suggest that these
animals developed an adaptive immunity.
SM83 rapidly kills cancer cells floating in the ascites by
a non-apoptotic mechanism. To investigate the mecha-
nism of SM83 activity in vivo, the ascitic fluid from mice
injected with IGROV-1 cells and treated or not with SM83 for
3, 6 or 24 h was collected and tumour cells were counted.
The results showed a striking decrease (Po0.001) in the
total number of ascites tumour cells in SM83-treated mice at
24 h compared with control untreated mice, without appreci-
able changes at 3 or 6 h (Figure 3a). Autopsy revealed no
adhesion of single cancer cells to the peritoneal wall nor
migration outside the peritoneum. Furthermore, we detected
a significant increase of human cytokeratin-18 (Po0.0001),
a protein released from dying human epithelial cells, in the
Figure 1 SM83 induces apoptosis in vitro when combined with TRAIL. (a) Chemical structure of the dimeric SM SM83. (b) IGROV-1 cells were treated with 0.1 or 1.0mM
SM83 alone or in combination with 2 or 10 ng/ml TRAIL. Cell growth is expressed as a percentage relative to cells mock-treated with vehicle. Values are mean and S.D. from
one experiment representative experiment of three performed. (c and d) Western blot analysis of XIAP, cIAP1, cIAP2 and cleaved PARP (Cl PARP) in IGROV-1 cells treated 3
or 24 h with SM83 (c) or SM59 (SM-164) (d) in the absence or presence of 10 ng/ml TRAIL. Actin is shown as loading control. Arrow, specific XIAP band
Figure 2 Treatment with SM83 in monotherapy increases the survival of mice bearing cancer ascites. (a) Nude mice were injected i.p. with IGROV-1 cells and left
untreated (J) or treated 5 times a week, for 2 consecutive weeks starting the day after injection, with 5 mg/kg SM83 (m), 2.5 mg/kg TRAIL (r) or with the same doses of
SM83 and TRAIL together (’). One experiment representative of two performed is shown. Each treatment group contained seven mice. Survival curve for SM83-treated mice
and controls. (b) Survival curve for SM59-treated and control mice. Untreated (J) or treated with SM SM59 (r). (c) The formation of ascites was checked by monitoring body
weight on day 17. (d and e) BALB/c mice were injected with Meth A cells and, starting on day 7, were treated daily with 5mg/kg SM83. (d) The formation of ascites was
checked by monitoring body weight on day 13. The horizontal line represents the mean. (e) Survival curve for untreated (K) or SM83-treated mice (J) starting from day 7
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serum of mice treated for 24 h (Figure 3b), suggesting
that SM83 triggered tumour cell death. Corroborating these
in vivo findings, western blot analysis of proteins from floating
tumour cells within the ascites confirmed that SM83 induced
the degradation of cIAP1 and cIAP2, but not of XIAP
(Figure 3c).
To understand the mechanism of cell death accounting
for the decrease in the number of floating tumour cells
within ascites, we examined the expression of mediators of
apoptosis in these cells at different time points. At 24 h, SM83
treatment led to only a faint increase of cleaved PARP, no
evidence of cleaved, active caspase-8 (which was expected
because these cells are killed in vivo by SM monotherapy30)
and only a modest effect on cleavage of caspase-3
(Figure 3d). In contrast, cells treated with TRAIL showed a
greater activation of these apoptotic markers even though
TRAIL was ineffective in reducing the ascitic cell number
(Supplementary Figure S1). In an attempt to detect the
apoptotic events, western blotting was done on the cells
collected after 3 and 6 h of treatment (Figure 3e). Also in this
case, SM83 caused the complete degradation of cIAP1 and
cIAP2, but there was only a faint accumulation of the cleaved
forms of PARP, caspase-8 and caspase-3. This low activation
of the apoptotic cascade suggested that the cause of death of
the ascites tumour cells was not primarily apoptotic.
To assess the possibility that autophagy – another
mechanism that can cause cell death when abnormally and
continuously activated – was responsible for the loss of
ascites tumour cells, we measured the levels of beclin-1 and
cleaved LC3B. Treatment with SM83 did not increase
the levels of these proteins (Supplementary Figure S2),
suggesting that autophagy is not involved in SM83-induced
tumour cell death.
SM83 triggers an inflammatory event in vivo. Having
excluded apoptosis and autophagy in SM83-mediated
cell death, we investigated the involvement of necrosis by
measuring the levels of murine inflammatory cytokines in the
ascites. There was a basal level of murine TNF in the ascites
of untreated mice, whereas in mice treated with SM83, the
level of murine TNF was significantly higher at 3 and 6 h but
not at 24 h (Figure 4a). On the contrary, human TNF was not
affected by SM83 treatment (Supplementary Figure S3).
We tested the relevance of TNF in this model by pretreating
mice with two inhibitors of TNF, etanercept and infliximab.
Etanercept at the higher dose tested completely blocked the
cytotoxic effects of SM83 (Figure 4b), without preventing
SM83-triggered degradation of cIAPs (Figure 4c). Pretreat-
ment of mice with infliximab, instead, did not block the
cytotoxic effects of SM83 on ascites tumour cells (data not
shown), probably owing to its lower affinity for mouse TNF or
to an insufficient concentration. Overall, these data suggest
that SMs are effective in vivo by stimulating the release of
murine TNF that activates the TNF receptor leading to
the creation of a pro-inflammatory microenvironment.
Accordingly, the murine inflammatory cytokines IL-1b
(Figure 4d) and IFN-g (Figure 4e) were upregulated in the
peritoneal ascites in response to SM83 administration.
Figure 3 SM83 kills ascites tumour cells through a rapid, non-apoptotic event. Ascitic fluids were collected from nude mice injected with IGROV-1 cells and left untreated
or treated with a single injection of SM83 (5 mg/kg). (a) Number of tumour cells within the ascites of untreated animals (n¼ 11) or of animals treated for 3 (n¼ 4), 6 (n¼ 4) and
24 h (n¼ 9). Data are mean and S.D. (b) Levels of human cytokeratin-18 in the serum collected 24 h after a single dose of SM83 (5 mg/kg) or no treatment. (c) Western blot of
apoptosis markers in IGROV-1 cells cultured in vitro or recovered from the ascites of control mice (n¼ 2) or mice treated with SM83 (n¼ 2) or TRAIL for 24 h. (d) Western blot
to detect activated apoptosis markers cleaved PARP (p89), caspase-8 (precursor p55 and cleaved form p43/41) and cleaved caspase-3 (p19/p17) in IGROV-1 cells cultured
in vitro or recovered from the ascites (24 h) of control mice (n¼ 2) and of mice treated with 5mg/kg SM83 (n¼ 2) or 10mg/kg TRAIL. (e) Western blot of apoptotic markers in
tumour cells collected from the ascites of untreated mice (n¼ 2) or from mice treated for 3 or 6 h with SM83 (n¼ 2 for both) or with TRAIL for 24 h. Arrow, specific band
for XIAP
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In contrast, levels of the immunosuppressive cytokines IL-10
(Figure 4f), transforming growth factor-b (Figure 4g) and IL-4
(Figure 4h) remained mostly unchanged, with the exception
of IL-4 that increased significantly at 24 h; this increase could
be explained by the anti-inflammatory role of this cytokine,
secreted after 24 h to restrain the strong inflammation in
process.
SM83 promotes macrophage activation towards an
M1-like phenotype. To evaluate whether the pro-
inflammatory effect of SM83 depends on the activation
of tumour-associated macrophages, bone marrow (BM)-
derived macrophages (BMDM) from BALB/c mice were
treated in vitro with SM83, and the cell supernatants were
assayed for TNF and IL-1b. SM83 induced the secretion of
TNF starting at 6 h (Figure 5a) and of IL-1b at 24 h
(Figure 5b). Moreover, as macrophage activation is regulated
by NF-kB, we checked whether SM83 activated this pathway
using a macrophage cell line stably expressing a luciferase
reporter gene under control of the NF-kB-response element.
NF-kB activation was detectable after 3 h of treatment with
SM83 but returned to basal levels at 24 h (Figure 5c).
In agreement with an earlier study,31 SM83 treatment also
promoted the death of BMDM through necroptosis, which
was seen 24 h after treatment both morphologically
(Figure 5d, second panel) and with the CellTiter-Glo assay
Figure 4 SM83 treatment induces the expression of inflammatory cytokines in vivo. Nude mice were injected i.p. with IGROV-1 cells and treated or not with a single dose
of 5mg/kg SM83; ascites was collected 3, 6 and 24 h after SM83 administration. (a) SM83 transiently increased the level of murine TNF measured by ELISA. (b) SM83
treatment reduced ascites cell counts but this action was blocked when TNF was sequestered with the higher dose of etanercept (P¼ 0.0118 relative to treated with SM83
alone). (c) Western blots of ascites tumour cell protein from untreated mice and mice treated with SM83 alone or in combination with 150mg/kg etanercept. Arrow, specific
band for XIAP. (d–h) ELISA results for IL-1b (d), IFN-g (e), IL-10 (f), transforming growth factor-b (TGF-b) (g) and IL-4 (h) in the ascitic fluid of mice treated as above.
Results for IL-10 are shown as fold induction owing to the lack of recombinant protein standard
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(Figure 5e, first bar). This cytotoxicity was prevented
by pretreatment with necrostatin-1, a specific inhibitor of
receptor-interacting protein-1 (a crucial mediator of necrop-
tosis), but not by the pan-caspase inhibitor z-vad-fmk,
which actually increased BMDM death (Figures 5d and e).
Overall, these data suggest that macrophages could
be the first target of SM83 activity that fosters their
production of pro-inflammatory M1-like molecules such as
TNF and IL-1b.
To exclude the possibility that the SM83-induced IL-1b
secretion was due to contamination with lipopolysaccharides
(LPS), by the stimulation of toll-like receptor-4 (TLR432), we
prepared BMDM from TLR4-knockout (KO) mice and found
that IL-1b was secreted to a similar extent as it was secreted
from BALB/c cells (Supplementary Figure S4). Furthermore,
SM83 preparations for injection were found to not contain
detectable levels of LPS on the Endosafe-PTS (Charles River
Laboratories, Calco, Italy) test (data not shown). These
results indicate that the SM83-induced IL-1b production was
not due to LPS contamination.
Bystander accumulation of neutrophils in the ascites.
Having demonstrated a pro-inflammatory effect of SM83 in
the tumour microenvironment, we next evaluated whether
SM83 treatment affected the innate immune cells infiltrating
the ascites. To this end, we used immunofluorescence
to examine the expression of leucocyte antigens on
cells harvested from the ascites of nude mice. This assay
allowed us to identify both macrophages (CD11bþ Gr-1 )
and neutrophils (CD11bþ Gr-1þ ) in mice that were either
untreated or treated for 3 and 6 h before harvesting
(Figure 6a), without noticeable differences in cell density.
However, after 24 h of treatment, neutrophils (but not
macrophages) had massively accumulated in the ascitic
fluid (Figure 6a, Supplementary Figure S5). Neutrophils had
also infiltrated the tumour nodules (Supplementary Figure S6).
This massive neutrophil recruitment was likely because of
the presence, in the ascites, of high-mobility group box-1
(HMGB-1; Figures 6b and c) and TNF (Figure 4a). HMGB-1,
which is released during necrosis and immunogenic
cell death, behaves as an ‘alarmin’ that, together with TNF,
attracts and activates neutrophils.33 In our IGROV-1 model,
HMGB-1 was detected in the ascitic fluid starting 6 h after
SM83 treatment (Figure 6b) and was located within the
cytoplasm of dying tumour cells (Figure 6c).
Next, neutrophils were isolated from spleens of BALB/c
(wild-type) and TNF-receptor-1 (TNF-R1)-deficient mice
to investigate in vitro the role of neutrophils in the antitumoural
activity of SM83. In Transwell assays, the migration of
wild-type neutrophils towards ascites from SM83-treated
mice was greater than that from untreated mice (Figure 6d).
The HMGB-1 inhibitor partially reduced the migration,
whereas neutrophils from TNF-R1-deficient mice did not
migrate in response to ascites from SM83-treated mice.
Ascites from mice treated with SM83 activated wild-type
neutrophils to produce superoxide even in the presence of the
TNF blocker etanercept, whereas glycyrrhizin completely
blocked such activity (Figure 6e). These findings suggest
that neutrophil migration in the presence of ascites from
SM83-treated mice is stimulated by TNF while activation is
attributable to HMGB-1. The importance of TNF in neutrophil
migration was also shown in vivo, where etanercept pretreat-
ment blocked the recruitment of these cells into the ascites
(Supplementary Figure S5).
Figure 5 SM treatment activates macrophage and sensitises them to necroptotic death. (a and b) BALB/c BMDM (5 105) were seeded in 96-well plates, left to adhere
for 16 h and treated or not with 1mM SM83 for up to 24 h. SM83 treatment promoted the secretion of the pro-inflammatory cytokines TNF (a) and IL-1b (b). (c) NF-kB
activation by SM83 evaluated in the macrophage cell line RAW stably transfected with a NF-kB luciferase reporter gene. One representative experiment of two performed is
shown. Values are mean and S.D.; n¼ 3. (d and e) BALB/c BMDM were seeded in six-well plates, left to adhere for 16 h and treated with serial dilutions of SM83 in the
absence or presence of necrostatin-1 or z-vad-fmk to inhibit necroptosis or apoptosis, respectively. (d) Representative images showing cell morphology after 24 h of treatment.
(e) Cell viability after treatments evaluated using the CellTiter-Glo assay
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Figure 6 SM83 treatment promotes peritoneal neutrophil recruitment and activation. Cells were harvested from the ascitic fluid of mice treated with 5 mg/kg SM83.
(a) Immunofluorescence for CD11b (green) and Gr-1 (red) was performed on Cytospin cell preparations. SM83 treatment induced a massive recruitment of neutrophils
(CD11bþ Gr-1þ ) at 24 h but not at earlier time points. (b) Dot blot of HMGB-1 (left panel) was performed on cleared ascitic fluids collected from untreated (un) or treated mice
at 3, 6 and 24 h after a single injection of 5mg/kg SM83. Right panel, loading control. (c) Infiltration of neutrophils (Gr-1; red) and HMGB-1 expression in dying tumour cells
(green) in ascites untreated (upper row) and treated for 24 h (lower row) with a single injection of SM83. Left and right panels show two different magnifications ( 10 and  40).
(d) PMN migration assessed by Transwell assay. Wild-type PMN from BALB/c mice (WT) or TNF-R1-deficient PMN from TNF-R1-KO mice (KO) were seeded into the upper
chamber in the absence or presence of the HMGB-1 inhibitor glycyrrhizin (GLZ), whereas the ascitic fluid of mice untreated or treated for 6 h (1:20 in medium) was added to the
lower chamber of the Transwell insert. PMN were left to migrate overnight, harvested and counted. (e) Activation of wild-type PMNs was colorimetrically evaluated on the basis
of the ability of cells to oxidise the cytochrome c in presence of the ascitic fluid collected from mice 6 h after treating with a single injection of SM83. The experiment was also
performed in the presence of GLZ and the TNF inhibitor etanercept. (f) Tumour cell counts in the ascites of untreated mice (UN), mice treated with a single injection of SM83
alone or mice treated with SM83 24 h after depletion of neutrophils by injection with the 1A8 mAb. (g) BALB/c mice were injected i.p. with Meth A cells and treated with 1A8
alone (’) or in combination with 5 mg/kg SM83 (&), starting from day 7
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Considering that, in certain conditions, neutrophils can be
responsible for tumour cell killing,34,35 we depleted ascites-
bearing mice of neutrophils before SM83 treatment. In nude
mice bearing IGROV-1 ascites, neutrophil depletion
did not impede the ability of SM83 to reduce the number of
floating tumour cells in the ascites (Figure 6f). Furthermore, in
immunocompetent BALB/c mice bearing Meth A ascites,
depletion of neutrophils (Supplementary Figure S7) did not
prevent SM83 from prolonging survival (Figure 6g), even
though these mice have CD8þ T cells that are known to
support the activity of neutrophils.36 On the contrary,
neutrophil depletion improved the efficacy of SM83 treatment
by significantly augmenting the overall survival of mice
treated with SM83 (P¼ 0.0458 versus 1A8 alone). These
results support the notion that, in our models, neutrophil
recruitment is a bystander effect due to SM83-induced
TNF secretion. The accumulation of neutrophils has no role
in SM-dependent cancer cell killing but rather, at least in the
Meth A model, could be in some way detrimental to the host.
In conclusion, our work shows that SM83 acts in vivo in
cancer ascites by reverting macrophages from an M2-like
phenotype, supporting the tumour, to an M1-like phenotype,
endowed with antitumour activity. M1 macrophages secrete
cytokines such as TNF, IL-1b and IFNg that cause a rapid
TNF-dependent necrotic death of the ascites cancer cells
(Figure 7); subsequently, the dying cells release HMGB-1
that, together with TNF, stimulates a massive infiltration of
neutrophils.
Discussion
In this study, we describe the in vivo activity of newly
synthesised SM SM83 in two murine xenograft models
of cancer ascites. We show that SM83 is active as
monotherapy in vivo on human and murine cancer cells that
are refractory to SMs in vitro, and demonstrate that these cells
die through a non-apoptotic, TNF-dependent mechanism.
We also provide evidence that SM83 exerts its activity by
inducing inflammation and immune cell activation, resulting in
immunogenic death of cancer cells. Moreover, our study
shows that the activity of SM83 (and possibly other SMs) in
the complex in vivo environment is different from that already
observed in vitro.
The activity of SMs in vitro has been widely shown to
depend on the secretion of TNF from tumour cells leading
to apoptosis in an autocrine manner.17,18 Our in vivo work
confirms that the antitumoural activity of SM83 depends on
TNF production. However, in our xenograft models, TNF
originated primarily from the host rather than from the tumour
cells. TNF was secreted by the immune cells, and by
macrophages in particular, and this effect was preceded
temporally by activation of the NF-kB-response element.
Following SM83 treatment, macrophages acquired an M1-like
phenotype characterised by the release of pro-inflammatory
cytokines such as TNF and IL-1b. Both cytokines have been
associated with the cytotoxic activity of macrophages on
tumour cells.23,37 Our experiments show that SM83 treatment
increased the concentration of these cytokines in the ascites
without a major influx of macrophages. Thus, SM83 treatment
may revert existing M2 macrophages to the M1 phenotype
rather than recruit new macrophages to the ascites.
A mechanistic interpretation of these results (Figure 7) is that
the cytokines secreted by M1 macrophages cause necrotic
death of the ascites cancer cells; the dying cells release
HMGB-1 that, together with TNF, recruits neutrophils as a
side effect rather than a needed step in the antitumoural
activity of SM83.
In tumour microenvironment, including ovarian cancer,
macrophages acquire an M2-like phenotype.38,39 Neverthe-
less, some authors have proposed various strategies23,24 that
are able to interchange the status of macrophages towards an
efficient antitumour response. On this line, it has also been
Figure 7 Proposed mechanism of action of SM83 in cancer ascites. SM83 stimulates the reversal of macrophages from M2 to M1 phenotype. TNF secreted by M1
macrophages triggers necrotic death of the cancer cells within the ascitic fluid; the dying cells release HMGB-1 that, together with TNF, recruits neutrophils
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shown the possibility of increasing efficacy of standard
therapies interfering with M2 macrophages,40 particularly
in tumours whose progression strictly relies on their support
such as ovarian carcinomas. These tumours establish a
complex relationship with the associated immune cells within
the ascites,41 developing an immunosuppressive microenvi-
ronment elicited by macrophages. Thus, in ovarian cancer,
the re-polarisation of macrophages or the inhibition of their
recruitment could be a new effective therapeutic strategy.
Our results suggest that SMs regulate the immune
response to cancer ascites by polarising macrophages and
thus have therapeutic potential. In fact, Smac/DIABLO42
and its mimetic SM83, as shown here, trigger necrotic
or necroptotic cell death. Necrotic cells, different from
apoptotic ones, release a non-oxidised, immunogenic form
of the alarmin HMGB-143 that activates dendritic cells by
engaging receptor for advanced glycation endproducts,
TLR4, TLR7 and TLR9 receptors.44 Furthermore, necrotic
cells can prime CD4þ T cells, essential for the development
of an adaptive immune response.45 The possibility that
SM83-induced necrosis primed an adaptive immune
response is raised by our results using BALB/c-immunocom-
petent mice bearing Meth A ascites. Some of these mice were
cured by SM83 treatment and, when challenged with
a new, double dose of Meth A cells, they did not form another
ascites, suggesting that they were immune to Meth A
sarcoma cells.
In conclusion, our data demonstrate that the SM SM83
is active in monotherapy by promoting inflammation
and immunogenic cell death. These observations provide
an explanation for why SMs increase the effectiveness of
standard therapies, namely by stimulating the immune
system. Finally, the evidence that SMs can induce an
inflammatory response and activate the immune system
provides an interpretation of why SMs can be more effective
in vivo than in vitro,11,46 and our results in cancer cell killing.
Materials and Methods
SMs, cell lines and mice strains. The compounds used in this study
were SM83 (called 9a elsewhere29,47), SM59 (also called SM-16448) and TRAIL.
Recombinant TRAIL was purchased from Enzo Life Sciences (Farmingdale, NY,
USA), whereas SM83 and SM59 were synthesised by CISI scrl (purity499%).
Synthesis and chemical structure of these SMs have been described elsewhere.28,29
Human ovarian carcinoma IGROV-1 and A2780, lung cancer H460, colon cancer
SW48, HCT-116 and DLD-1, and murine sarcoma Meth A cell lines were cultured
in vitro with RPMI plus 10% foetal calf serum. The murine macrophage cell line RAW
264.7, stably transfected with an NF-kB luciferase reporter plasmid, was cultured in
DMEM plus 10% foetal calf serum.
KO C57/BL6 mice strains deficient in TNF-R1 (TNF-R1-KO49) or in TLR4-KO50
and female athymic Swiss nude mice, all 8–10 weeks of age (Charles River
Laboratories), were maintained in laminar flow rooms keeping temperature and
humidity constant. Female BALB/c mice 7–8 weeks of age (Charles River
Laboratories) were housed in filter-top cages. Room sentinels were checked for
pathogens every 6 months by Charles River Laboratories staff. Experiments were
approved by the Ethics Committee for Animal Experimentation of the Fondazione
IRCCS Istituto Nazionale dei Tumori of Milan according to institutional guidelines.
Cell treatments and assays. Cells were plated at a density of about 60%
and grown overnight before being treated with SM83 or SM59 in the absence or
presence of 2 or 10 ng/ml TRAIL. Cell growth was determined after 3 days by cell
counting, whereas viability was tested using the CellTiter-Glo (Promega Italia srl,
Milan, Italy) assay for ATP after 24 h of treatment. For apoptosis assays, cells
were harvested after 3 or 24 h of treatment and used in western blotting.
Western blotting. Cells were harvested at the end of the treatment and
lysed in 125mM Tris HCl pH 6.8, 5% SDS by boiling; protein concentration was
quantified. Lysates (50mg) were fractionated by SDS-PAGE and proteins were
blotted onto PVDF membranes. Free protein-binding sites were blocked with 5%
non-fat dry milk in phosphate-buffered saline (PBS) and the membranes were
incubated overnight with primary antibodies diluted in non-fat dry milk-PBS.
The primary antibodies used were directed against: cleaved caspase-3, beclin-1,
cleaved PARP and LC3B (Cell Signaling Technology, Danvers, MA, USA);
caspase-8 (Enzo Life Sciences); XIAP and cIAP2 (BD Biosciences, Milan, Italy),
b-actin (Sigma, Rome, Italy); and cIAP1 (R&D Systems, Minneapolis, MN, USA).
After washing, the membranes were exposed to horseradish peroxidase-linked
secondary antibody (GE Healthcare, Milan, Italy) for 1 h and the bound antibodies
were detected using ECL (Thermo Scientific, Rockford, IL, USA).
Animal models of cancer ascites. The in vivo effects of SMs were tested
using two murine xenograft models of ovarian cancer. In one model, human
ovarian carcinoma IGROV-1 cells are injected i.p. into athymic nude mice.51
The cells adapt to grow i.p. and are maintained by i.p. serial passages of ascitic cells.
Mice develop haemorrhagic ascites and diffuse carcinomatosis and eventually
die.51 In order to assess the effects of SMs on survival, mice were inoculated i.p.
with 2.5 106 cells in 0.2 ml saline and, starting the day after cell injection,
injected i.p. with the compounds (dissolved in saline) at 5 mg/kg body weight, once
daily for 5 days per week for 2 weeks (qdx5/wx2w). The animals were inspected
and weighed daily. The progression of ascites was assessed from an increase in
body weight (measured on day 17). For ethical reasons, they were killed before
impending death, recognised by their suffering status and loss of reactivity to
external stimuli. The day of killing was taken as the day of death for calculating the
median survival time. The antitumour activity of treatments was expressed as
the ratio of median survival time in treated mice to that of untreated control
mice 100 (T/C%).
In the other ascites model, murine Meth A cells are injected i.p. into
immunocompetent syngeneic BALB/c mice.52 Here, 2 105 Meth A cells were
injected i.p., and treatment, starting 7 days later, consisted of five consecutive daily
i.p. injections of SM83 at a dose of 5mg/kg body weight. The progression of ascites
was assessed from both an increase in body weight (measured on day 13) and
overall survival, as calculated above. Mice in whom the ascites resolved and did not
relapse within 60 days were considered to be cured, and were challenged with a
new injection of 4 105 Meth A cells.
To assess the effects of SMs on ascites tumour cells, athymic nude mice were
injected with IGROV-1 cells as above. Ten days after IGROV-1 inoculation, ascites-
bearing mice were treated with a single injection of SM83 (5 mg/kg) or left untreated;
in some experiments, mice were pretreated 1 h before SM83 administration by i.p.
injection with one of two TNF inhibitors: 5 or 150mg/kg etanercept (Wyeth
Pharmaceuticals, Collegeville, PA, USA)53 or 5 mg/kg infliximab (Schering-Plough,
Milan, Italy). Mice were killed 3, 6 or 24 h after SM83 treatment, and ascitic fluid was
collected with a heparinised syringe, transferred to a centrifuge tube on ice and
centrifuged to pellet the cells for blotting. The supernatant was removed and stored
at  80 1C until it was assayed for cytokines (human and murine TNF, and murine
IL-1b, IL-4, IL-10, IFNg and transforming growth factor-b enzyme-linked
immunosorbent assay (ELISA) kits (Affymetrix, San Diego, CA, USA) or used in
blotting and in neutrophil assays. The pellet was suspended in 0.17M ammonium
chloride for 10min at 41 1C to lyse red blood cells; after washing in saline, the
remaining tumour cells were counted using the trypan blue exclusion assay and
used in immunofluorescence. Death of IGROV-1 cells was also checked by
quantifying human cytokeratin-18, a cytokeratin released by dying cells, in the serum
collected from killed ascites-bearing mice using M65 ELISA (Enzo Life Sciences).
Animals were subjected to autopsy to search for adherent tumour cells or
extraperitoneal migration. As IGROV-1 cells injected i.p. in nude mice also form
solid nodules, these were collected and fixed in formalin. After 24 h, tumours were
washed in PBS and kept in 70% ethanol until they were embedded in paraffin and
prepared for haematoxylin and eosin staining.
To deplete neutrophils, nude mice bearing IGROV-1 ascites were injected
i.p. with the anti-Ly-6G antibody (clone 1A8; Affymetrix) 24 h before SM83
administration. In the Meth A model, mice were injected with 20 mg 1A8 antibody
every second day, for 14 consecutive days, starting one day before SM83 treatment
(day 7). The efficiency of polymorphonuclear leucocytes (PMNs) depletion in nude
mice was tested by sampling the bone marrow (BM) 24 h after injection of the
anti-Ly-6G antibody. Cells were double-stained with anti-CD11b/Ly-6G and cell
populations were quantified by flow cytometry.54
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Macrophage primary cultures and reporter gene assays.
BM precursors were obtained from BALB/c and TLR4-KO mice and used to
isolate macrophages as previously described.26 Briefly, macrophages were
isolated from the precursors by cultivation in RPMI medium 10% foetal calf serum
containing 5 ng/ml macrophage colony-stimulating factor. On day 5, the medium
was replaced with fresh medium containing macrophage colony-stimulating factor.
On day 7, adherent cells were harvested and phenotypically characterised by
immunofluorescence using mAb to the macrophage markers CD11b and F4/80
(BD Biosciences). Up to 90% of the adherent population consisted of BMDM.
For in vitro experiments, 5 105 BMDM were seeded in six-well plates, allowed
to attach for 1 h at 37 1C and then treated or not with 1mM SM83. The release of
TNF and IL-1b to the culture medium, after 3, 6 and 24 h, was evaluated using
ELISA kits (Affymetrix). In viability experiments, 1 104 cells were seeded in
96-well plates and exposed to serial dilutions of SM83 in the absence or presence of
either 50mM necrostatin-1 (Enzo Life Sciences) or 20 mM z-vad-fmk (Enzo Life
Sciences). After 24 h, cells were examined morphologically by microscopy and
tested for viability using the CellTiter-Glo (Thermo Scientific) assay.
In other experiments, 104 RAW 264.7 macrophages were plated in 96-well
plates, grown for 16 h and then treated or not with 1mM SM83 for up to 24 h.
The activation of the NF-kB promoter was assayed using the Dual-Luciferase
Reporter Assay System (Thermo Scientific).
Immunofluorescence and dot blotting. Floating cells harvested from
the ascites were prepared for double-marker immunofluorescence by centrifuga-
tion on slides using a Cytospin cytocentrifuge. Briefly, acetone-fixed cells were
re-hydrated in PBS and incubated 1 h with a primary antibody. Cells were then
washed in PBS and incubated for 30min with the appropriate Alexa Fluor
488-conjugated secondary antibody. After washing, slides were incubated for
30min with another primary antibody, washed and incubated for 30min with an
Alexa Fluor 546-conjugated secondary antibody. The primary antibodies used
were: rat anti-mouse CD11b mAb (1:200; BD Biosciences); rat anti-mouse Ly-6G
mAb (1:200; BD Biosciences); and rabbit anti-HMGB-1 Ab (1:400; Abcam,
Cambridge, UK). In some experiments, nuclei were stained with 40,6-diamidino-
2-phenylindole. Slides were mounted with Prolong medium (Life Technologies,
Monza, Italy) and examined under a RADiance-2000 (Bio-Rad, Milan, Italy) Nikon-
TE300 laser scanning confocal microscope (Nikon Instruments S.p.A, Florence, Italy).
For dot blotting, ascitic fluid samples cleared of cells were spotted on PDVF
membranes and let to dry. After saturation with non-fat dry milk-PBS, filters were
hybridised with anti-HMGB-1 Ab (Abcam, 1:2000). The HMGB-1 was then detected
as for western blotting.
Spleen neutrophil preparation and assays. Neutrophils were obtained
from BALB/c (wild-type) or TNF-R1-KO mice through immunomagnetic cell
separation of a spleen cell suspension, using the Anti-Ly-6G MicroBead Kit
(Miltenyi Biotec, Bologna, Italy), as already described.54
Migration of neutrophils PMNs was tested using the Transwell system (Corning,
Tewksbury, MA, USA). Briefly, 5 105 PMNs were placed in serum-free RPMI in
the upper chamber of the Transwell insert. The lower chamber was filled with ascites
(1:20) or TNF in serum-free DMEM. PMNs were allowed to migrate for 24 h and then
collected from the lower chamber. In some cases, experiments were performed by
adding 100mM of the HMGB-1 inhibitor glycyrrhizin (Sigma-Aldrich, St. Louis, MO,
USA) to the top chamber.55
Neutrophil activation by cleared ascites was evaluated by measuring the rate of
formation of superoxide. Briefly, neutrophils (2 106/0.1ml cells/PBS solution) were
incubated with 20ml of cytochrome c (0.1mM final, bovine, Sigma), 20ml of ascites or
10mg/ml of PMA (as positive control for the neutrophil stimuli) in 1.76ml PiCM-G buffer
(138mMNaCl, 2.7mM KCl, 0.6mM CaCl2, 1.0 mMMgCl2, 5mM glucose and 10mM
NaH2PO4/Na2HPO4, pH 7.4). The mixture was added to cuvettes for spectro-
photometer and absorbance was read at 550 nm every 15min as described.56
Statistical analyses. For survival analyses, the percent survivorship over
time was estimated using the two-sided Kaplan–Meier product method; differences
between groups were compared using the log-rank test. In other analyses,
differences between groups were tested for significance using a two-tailed
unpaired t-test. A value of Po0.05 indicated significance. The analyses were
performed using Graphpad Prism v.5.02 (GraphPad Software, La Jolla, CA, USA).
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